Report Library
All ReportsPost-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey
December 28, 2016
We conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom)
neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on
Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and
aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.
If you are a KOL Insight Subscriber, please access the survey from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
If you are a KOL Insight Subscriber, please access the survey from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: | Alzheimer's Disease (AD) |